RECRUITING

Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or endometrial cancer at NYPH and WCM for routine clinical care and to make these available for future use for molecular and mechanistic studies.

Official Title

Discovering New Targets for Hereditary and Sporadic Colorectal and Endometrial Cancer Risk Reduction

Quick Facts

Study Start:2019-05-29
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06096688

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of a Hereditary Cancer Syndrome by positive genetic testing and/or clinical criteria to undergo an endoscopy procedure (esophagoduodenoscopy and/or colonoscopy/flexible sigmoidoscopy), or endometrial screening procedure (transvaginal ultrasound and/or hysteroscopy and/or endometrial biopsy), OR
  2. * Individuals coming to Weill-Cornell Medicine/NYPH to undergo an endoscopy procedure, transvaginal ultrasound, or hysteroscopy for average-risk (population-based) recommendation OR
  3. * Individuals diagnosed with colorectal cancer or endometrial cancer coming to Weill- Cornell Medicine/NYPH for surgical treatment OR
  4. * Individuals coming to Weill-Cornell Medicine/NYPH for care such, as but not limited to, diagnostic testing, clinic and/or treatment visit.
  5. * Willingness and ability to sign informed consent.
  6. * Ability to read/understand English, Spanish, and/or simplified Chinese.
  7. * Patients who are included in the NYPH CADC GI or have signed a waiver to include biospecimens in research studies at NYPH.
  1. * under 18 years old
  2. * does not meet criteria listed above

Contacts and Locations

Study Contact

Steven M Lipkin, MD, PhD
CONTACT
212-746-4014
stl2012@med.cornell.edu
Melissa K Frey, MD, MS
CONTACT
646-697-6621
mkf2002@med.cornell.edu

Principal Investigator

Steven M Lipkin, MD
PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University

Study Locations (Sites)

NYP/Weill Cornell Medicine
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Weill Medical College of Cornell University

  • Steven M Lipkin, MD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-05-29
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2019-05-29
Study Completion Date2026-12-31

Terms related to this study

Keywords Provided by Researchers

  • personal and family history
  • genomic/epigenetic
  • polyps
  • carcinomas
  • Hereditary Cancer Syndromes
  • mucosa
  • blood serum markers
  • chemoprevention
  • registry

Additional Relevant MeSH Terms

  • Colorectal Cancer
  • Endometrial Cancer
  • Hereditary Cancer Syndromes